Home » Stocks » RVMD

Revolution Medicines, Inc. (RVMD)

Stock Price: $30.19 USD -1.34 (-4.25%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $30.39 +0.20 (0.66%) Oct 30, 6:27 PM

Stock Price Chart

Key Info

Market Cap 1.99B
Revenue (ttm) 46.17M
Net Income (ttm) -74.15M
Shares Out 65.93M
EPS (ttm) -21.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $30.19
Previous Close $31.53
Change ($) -1.34
Change (%) -4.25%
Day's Open 31.29
Day's Range 29.65 - 32.11
Day's Volume 208,834
52-Week Range 17.35 - 47.14

More Stats

Market Cap 1.99B
Enterprise Value 1.70B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 65.93M
Float 42.04M
EPS (basic) n/a
EPS (diluted) -21.25
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.37M
Short Ratio 4.34
Short % of Float 8.00%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 43.11
PB Ratio 5.79
Revenue 46.17M
Operating Income n/a
Net Income -74.15M
Free Cash Flow n/a
Net Cash 292.57M
Net Cash / Share 4.44
Gross Margin -90.36%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -17.30%
ROE -38.26%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(39.12% upside)
Current: $30.19
Target: 42.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth148.16%--
Gross Profit50.0420.17-
Operating Income-54.12-40.33-31.13
Net Income-47.66-41.79-31.13
Shares Outstanding2.772.301.72
Earnings Per Share-22.33-21.24-20.25
Operating Cash Flow-49.621.21-25.15
Capital Expenditures-2.39-1.50-1.58
Free Cash Flow-52.01-0.29-26.72
Cash & Equivalents12369.809.08
Net Cash / Debt12369.809.08
Book Value-153-108-67.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Revolution Medicines, Inc.
Country United States
Employees 106
CEO Mark A. Goldsmith

Stock Information

Ticker Symbol RVMD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RVMD
IPO Date February 13, 2020


Revolution Medicines, a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.